Search Results
Your search for The ASCO Post Staff matches 163 pages
Showing 1 - 50
William J. Gradishar, MD, on HR-Positive, HER2-Negative Breast Cancer: Management Update
William J. Gradishar, MD, of Robert H. Lurie Comprehensive Cancer Center of Northwestern University, details the fundamental shift in how clinicians now treat patients with endocrine-sensitive breast cancer, both advanced and early stage, by pairing antihormonal therapy with targeted treatment.
Judy C. Boughey, MD, on De-escalating Axillary Surgery After Chemotherapy for Breast Cancer
Judy C. Boughey, MD, of the Mayo Clinic, discusses findings from the I-SPY2 trial, which show that although the extent of residual disease and tumor biology in patients with breast cancer may impact outcomes, the type of axillary surgery after neoadjuvant chemotherapy does not (Abstract 3).
Kerollos N. Wanis, MD, PhD, on Risks for BRCA Mutation Carriers Treated With Breast-Conserving Therapy
Kerollos N. Wanis, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses a study in which he evaluated the risk of future ipsilateral and contralateral breast cancer events in a large cohort of patients with BRCA1 or BRCA2 mutations who chose breast conservation (Abstract 12).
Heather McArthur, MD, MPH, on Early-Stage High-Risk ER+/HER2− Breast Cancer: New pCR Results for Pembrolizumab and Chemotherapy
Heather McArthur, MD, MPH, of UT Southwestern Medical Center, discusses phase III findings from the KEYNOTE-756 trial, which shows that adding pembrolizumab to neoadjuvant chemotherapy increases pathologic complete response (pCR) rates in patients with early-stage, high-risk, estrogen...
Natália Polidorio, MD, PhD, on Triple-Negative Breast Cancer: Impact of Race on Treatment Efficacy
Natália Polidorio, MD, PhD, of Memorial Sloan Kettering Cancer Center, discusses findings on the impact of race on pathologic complete response in patients with early-stage triple-negative breast cancer who received neoadjuvant chemoimmunotherapy vs chemotherapy alone. Such targeted research may...
Hope S. Rugo, MD, on Triple-Negative Breast Cancer: Trial Update on Pembrolizumab Plus Olaparib vs Pembrolizumab Plus Chemotherapy
Hope S. Rugo, MD, of the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses data from the phase II KEYLYNK-009 study, which compared pembrolizumab plus olaparib vs pembrolizumab plus chemotherapy after induction with pembrolizumab plus chemotherapy...
Reshma Jagsi, MD, DPhil, on Early-Stage Breast Cancer: 5-Year Outcomes With Endocrine Therapy and Breast-Conserving Surgery
Reshma Jagsi, MD, DPhil, of Emory University Winship Cancer Institute, discusses the IDEA trial of endocrine therapy without radiotherapy after breast-conserving surgery for postmenopausal patients between the ages of 50 and 69 with stage I breast cancer. The regimen demonstrated a low risk of...
Seema Khan, MD, on Ductal Carcinoma in Situ: Central MRI and a 12-Gene Expression Assay to Optimize Local Therapy
Seema Khan, MD, of Northwestern University and the Robert H. Lurie Comprehensive Cancer Center, discusses the 5-year clinical outcomes of ECOG-ACRIN 4112, a prospective trial that supports the omission of radiotherapy after surgery in patients with ductal carcinoma in situ who have a low DCIS score ...
Peter Schmid, MD, PhD, on Early-Stage TNBC: Updated Survival Results From KEYNOTE-522
Peter Schmid, MD, PhD, of Queen Mary University of London and Barts Cancer Institute, discusses phase III findings from KEYNOTE-522 showing that neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab continues to show a clinically meaningful improvement in event-free...
Cynthia X. Ma, MD, PhD, on Metastatic Breast Cancer: Early Results on Copanlisib, Fulvestrant, and Abemaciclib
Cynthia X. Ma, MD, PhD, of Washington University School of Medicine in St. Louis, discusses phase I findings showing the safety and tolerability of copanlisib and fulvestrant in combination with continuous or intermittent abemaciclib in patients with estrogen receptor–positive, HER2-negative...
Hope S. Rugo, MD, on Advanced Breast Cancer: Patient-Reported Outcomes From the CAPItello-291 Trial
Hope S. Rugo, MD, of the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses patient-reported outcomes from the phase III CAPItello-291 study; the trial centered on adding capivasertib to fulvestrant in patients with aromatase inhibitor–resistant,...
Eleftherios P. Mamounas, MD, on Locoregional Irradiation, Axillary Lymph Node Involvement, and Conversion to Negative Nodes
Eleftherios P. Mamounas, MD, of Orlando Health Cancer Institute, discusses primary outcomes from the NRG Oncology/NSABP B-51/RTOG 1304 study of locoregional irradiation in patients with biopsy-proven axillary node involvement at presentation who become pathologically node-negative after neoadjuvant ...
Daniel Kates-Harbeck, MD Candidate, and Nadia Harbeck, MD, PhD, on Personalizing Breast Cancer Management With AI: Novel Approach to Predicting Outcomes
Nadia Harbeck, MD, PhD, of LMU University Hospital and Ludwig Maximilian University of Munich, and Daniel Kates-Harbeck, of the West German Study Group and an MD Candidate at Ludwig Maximilian University of Munich, discuss a learning-based neural network developed by Mr. Kates-Harbeck to predict...
Luca Gianni, MD, on Locally Advanced, HER2-Positive Breast Cancer: New Data on Neoadjuvant Therapy and Atezolizumab
Luca Gianni, MD, of Milan’s Fondazione Michelangelo, discusses findings from the APTneo Michelangelo trial, which showed that adding atezolizumab to chemotherapy and trastuzumab plus pertuzumab did not significantly increase the rate of pathologic complete response (pCR) in women with HER2-positive ...
Oleg Gluz, MD, on Response to Endocrine Therapy: Findings From the ADAPTcycle Trial
Oleg Gluz, MD, of the West German Study Group and Breast Center Niederrhein, discusses the impact of age and ovarian function suppression in response to preoperative endocrine treatment for both pre- and postmenopausal patients with early-stage breast cancer. He describes ways in which the outcome...
Barbara Pistilli, MD, on HR+, HER2– Advanced Breast Cancer: Update on Capivasertib Plus a CDK4/6 Inhibitor and Fulvestrant
Barbara Pistilli, MD, of France’s Gustave Roussy, discusses a phase Ib analysis from the CAPItello-292 study, which showed capivasertib plus palbociclib plus fulvestrant was tolerable at all dose levels in heavily pretreated patients with hormone receptor–positive, HER2-negative advanced breast...
Sherene Loi, MD, PhD, on Biomarker Results in ER+, HER2– Primary Breast Cancer Following Neoadjuvant Chemotherapy With or Without Nivolumab
Sherene Loi, MD, PhD, of Australia’s Peter McCallum Cancer Centre, discusses an exploratory analysis of CheckMate 7FL which showed that patients with PD-L1–positive, high-risk, estrogen receptor–positive, HER2-negative primary breast cancer may achieve substantial pathologic complete response rates ...
Sherene Loi, MD, PhD, on Triple-Negative Breast Cancer: Phase II Study Results of Nivolumab, Carboplatin, and Paclitaxel
Sherene Loi, MD, PhD, of Australia’s Peter McCallum Cancer Centre, discusses recent data showing that for patients with stage I/II triple-negative breast cancer, 12 weeks of a neoadjuvant nonanthracycline chemotherapy regimen with nivolumab may be efficacious with either concurrent or lead-in...
Aditya Bardia, MD, MPH, on Early-Stage, High-Risk Breast Cancer: New Data on Pembrolizumab Plus Chemotherapy
Aditya Bardia, MD, MPH, of Massachusetts General Hospital Cancer Center, discusses phase III findings from the KEYNOTE-756 study, which showed that adding pembrolizumab to chemotherapy increases the pathologic complete response rate and lowers the residual cancer burden in patients with...
Daniel G. Stover, MD, on Early-Stage Breast Cancer: A Biomarker Analysis From the PALLAS Trial
Daniel G. Stover, MD, of The Ohio State University Comprehensive Cancer Center, discusses a biomarker analysis from the PALLAS adjuvant trial, which compared 2 years of the CDK4/6 inhibitor palbociclib with endocrine therapy vs endocrine therapy alone, as adjuvant treatment for patients with stage...
Senthil Damodaran, MD, PhD, on Locally Advanced or Metastatic Breast Cancer: Phase II Results on Futibatinib
Senthil Damodaran, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses final results from the FOENIX-MBC2 study of the efficacy and safety of futibatinib in patients with locally advanced or metastatic hormone receptor–positive, HER2-negative breast cancer harboring high-level...
Nicholas C. Turner, MD, PhD, on High-Risk Early-Stage Breast Cancer: Profiling Primary Tumors
Nicholas C. Turner, MD, PhD, of The Royal Marsden Hospital NHS Foundation Trust, and the Institute of Cancer Research, London, discusses the monarchE trial, which evaluated molecular profiling of archived primary tumor tissue from patients with hormone receptor–positive, HER2-negative,...
Gabriel N. Hortobagyi, MD, on Early Breast Cancer: Final Invasive Disease–Free Analysis From the NATALEE Trial
Gabriel N. Hortobagyi, MD, of The University of Texas MD Anderson Cancer Center, discusses findings from the NATALEE trial, which continued to demonstrate improved invasive disease–free survival with ribociclib plus a nonsteroidal aromatase inhibitor (NSAI) over a NSAI alone in patients with...
Amy Tiersten, MD, on Metastatic Breast Cancer: A Possible Chemotherapy-Free Front-Line Regimen
Amy Tiersten, MD, of the Icahn School of Medicine at Mount Sinai and Tisch Cancer Institute, discusses findings from the ASPIRE trial, which showed the combination of anastrozole, palbociclib, trastuzumab, and pertuzumab in the front-line setting was well tolerated and effective, with a clinical...
Sara A. Hurvitz, MD, on Metastatic Breast Cancer: New Data on Tucatinib and Trastuzumab Emtansine
Sara A. Hurvitz, MD, of Fred Hutchinson Cancer Research Center, University of Washington, discusses phase III findings of the HER2CLIMB-02 study, which showed the combination of tucatinib and trastuzumab emtansine improved progression-free survival in patients with previously treated,...
Nadia Harbeck, MD, PhD, on High-Risk Early Breast Cancer: Overall Survival Data on Abemaciclib Plus Endocrine Therapy
Nadia Harbeck, MD, PhD, of Munich’s LMU University Hospital and the Ludwig Maximilian University, discusses an interim analysis of the monarchE trial on adjuvant abemaciclib plus endocrine therapy for patients with hormone receptor–positive, HER2-negative, high-risk early breast cancer. The data...
Peter Schmid, MD, PhD, on Triple-Negative Breast Cancer: Updated Results on Pembrolizumab Plus Chemotherapy
Peter Schmid, MD, PhD, of Queen Mary University of London, discusses phase III findings from the KEYNOTE-522 study, which showed neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab continues to improve event-free survival compared with neoadjuvant chemotherapy alone in...
Aki Morikawa, MD, PhD, on Brain Metastases: New Findings on Predictive Drug Testing
Aki Morikawa, MD, PhD, of the University of Michigan, and her team explored the use of patient-derived organoids from breast cancer brain metastases to evaluate drug sensitivities in a clinically meaningful time frame. Along with molecular profiling, she says, this method may further personalize...
Lisa A. Carey, MD, and Javier Cortes, MD, PhD, on HER2-Positive Early Breast Cancer: Chemotherapy De-escalation Under Study in PHERGain Trial
Lisa A. Carey, MD, of the University of North Carolina at Chapel Hill, and Javier Cortes, MD, PhD, of the International Breast Cancer Center and Universidad Europea de Madrid, discuss phase II findings showing that one in three patients with HER2-positive early breast cancer may safely omit...
Lisa A. Carey, MD, and Dennis J. Slamon, MD, PhD, on Early Breast Cancer: Findings From the NATALEE Trial on Ribociclib Plus Endocrine Therapy
Lisa A. Carey, MD, of the University of North Carolina at Chapel Hill, and Dennis J. Slamon, MD, PhD, of the University of California, Los Angeles, discuss phase III study findings on ribociclib plus endocrine therapy as adjuvant treatment in patients with hormone receptor–positive, HER2-negative...
Jennifer A. Ligibel, MD, on Early Breast Cancer and Weight Loss: Results From the BWEL Trial
Jennifer A. Ligibel, MD, of Dana-Farber Cancer Institute, discusses a telephone-based weight loss intervention that induced clinically meaningful weight loss in patients with breast cancer who had overweight and obesity, across demographic and tumor factors. Additional tailoring of the intervention ...
Anita Mamtani, MD, on Axillary Dissection: For What Types of Breast Cancer Can It Be Avoided?
Anita Mamtani, MD, of Memorial Sloan Kettering Cancer Center, discusses study findings showing that axillary lymph node dissection was required by less than 2% of patients with cT1NO triple-negative or HER2-positive breast cancer having upfront surgery. There was no clear advantage of neoadjuvant...
Kari M. Rosenkranz, MD, on Breast Cancer: Impact of Breast Conservation on Local Recurrence
Kari M. Rosenkranz, MD, of Dartmouth Health, discusses findings from the ACOSOG Z11102 (Alliance) study, which showed that breast-conserving therapy is safe for patients with multiple ipsilateral breast cancer lesions, resulting in low recurrence rates. However, omitting adjuvant endocrine therapy...
Judy C. Boughey, MD, on Changes in Axillary Surgical Management: An I-SPY2 Analysis
Judy C. Boughey, MD, of the Mayo Clinic, discusses the decrease, over the past decade, of axillary lymph node dissection, especially in patients with node-positive breast cancer at diagnosis who had sentinel lymph node surgery after neoadjuvant chemotherapy. These findings are based on the records...
Lindsay L. Peterson, MD, on Exercise and Cancer Outcomes
Lindsay L. Peterson, MD, of the Washington University, St. Louis, discusses the value of physical activity in improving cancer prognosis, especially for patients with breast or colon cancer. Aerobic exercises and resistance training are recommended during and after treatment. Exercise may help...
Sherry X. Yang, MD, PhD, on Breast Cancer: New Recurrence Score Data From the TAILORx Trial
Sherry X. Yang, MD, PhD, of the National Cancer Institute, discusses findings from the TAILORx trial, which showed that, despite chemotherapy, patients with high recurrence scores continue to have a poor prognosis. This result suggests the need to develop new management strategies for patients with ...
Sherry X. Yang, MD, PhD, on Breast Cancer: New Recurrence Score Data From the TAILORx Trial
Sherry X. Yang, MD, PhD, of the National Cancer Institute, discusses findings from the TAILORx trial, which showed that, despite chemotherapy, patients with high recurrence scores continue to have a poor prognosis. This result suggests the need to develop new management strategies for patients with ...
Matthew P. Goetz, MD, on Breast Cancer: Interim Survival Results With Abemaciclib Plus a Nonsteroidal Aromatase Inhibitor
Matthew P. Goetz, MD, of Mayo Clinic, discusses recent data from the MONARCH 3 trial of patients with advanced hormone receptor–positive, HER2-negative breast cancer. The study, a second interim analysis, showed that longer overall survival was observed in both the intention-to-treat group as well...
Sean Khozin, MD, MPH, on Randomized Trials vs Real-World Evidence in Patients With Advanced Cancer
Sean Khozin, MD, MPH, of the Massachusetts Institute of Technology, discusses the “external validity deficits” of randomized clinical trials, which still involve only about 5% of adults with cancer, who may differ in important ways from real-world populations. Dr. Khozin describes the reasons for...
Prudence A. Francis, MD, on Premenopausal ER-Positive Breast Cancer: Past, Present, and Future
Prudence A. Francis, MD, of the Peter MacCallum Cancer Centre, discusses an update of the SOFT trial, which showed that adding ovarian function suppression (OFS) to adjuvant tamoxifen for premenopausal women with estrogen receptor (ER)-positive breast cancer reduces the risk of recurrence. OFS...
Andrea De Censi, MD, on Noninvasive Breast Cancer: 10-Year Results on Low-Dose Tamoxifen
Andrea De Censi, MD, PhD, of Italy’s E.O. Ospedali Galliera, discusses phase III findings showing that low-dose tamoxifen (so-called babytam) given for 3 years still significantly prevents recurrences from noninvasive breast cancer after a median of 7 years from treatment cessation. Babytam at 5...
Ann H. Partridge, MD, MPH, on Interrupting Breast Cancer Treatment to Attempt Pregnancy
Ann H. Partridge, MD, MPH, of Dana-Farber Cancer Institute, discusses results from the POSITIVE trial, which showed that a temporary interruption of endocrine therapy in women with hormone-responsive breast cancer in order to attempt pregnancy, does not affect short-term disease outcomes. The study ...
Mafalda Oliveira, MD, PhD, on Camizestrant vs Fulvestrant in Advanced Breast Cancer: New Phase II Results
Mafalda Oliveira, MD, PhD, of Spain’s Vall d’Hebron University Hospital and Institute of Oncology, discusses findings from the SERENA-2 trial, which compared the next-generation selective estrogen receptor degrader camizestrant to fulvestrant in patients with hormone receptor–positive,...
Marleen Kok, MD, PhD, on Early Breast Cancer: A Year in Review
Marleen Kok, MD, PhD, of the Netherlands Cancer Institute, discusses the most important advances in early breast cancer treatment during the past year for patients with triple-negative, HER2-positive, and estrogen receptor–positive disease. Dr. Kok also addresses long-term treatment toxicities and...
François-Clément Bidard, MD, PhD: Circulating Tumor Cells May Help Improve Outcomes in Metastatic Disease
François-Clément Bidard, MD, PhD, of the Institut Curie, discusses overall survival results from the STIC CTC trial. To guide the choice between chemotherapy and endocrine therapy for patients with metastatic, estrogen receptor–positive/HER2-negative breast cancer, researchers compared circulating...
Erica L. Mayer, MD, PhD, on Metastatic Breast Cancer: New Findings on Palbociclib After Prior CDK4/6 Inhibitor and Endocrine Therapy
Erica L. Mayer, MD, PhD, of Dana-Farber Cancer Institute, discusses findings from the PACE study of patients with endocrine- and CDK4/6 inhibitor–pretreated estrogen receptor–positive/HER2-negative metastatic breast cancer who were randomly assigned to fulvestrant alone; fulvestrant and...
Aditya Bardia, MD, MPH, on Elacestrant vs Standard-of-Care Endocrine Therapy in ER-Positive, HER2-Negative Breast Cancer
Aditya Bardia, MD, MPH, of Massachusetts General Hospital, discusses results from the phase III EMERALD trial, the first study to demonstrate improved progression-free survival vs standard of care in estrogen receptor (ER)-positive, HER2-negative metastatic breast cancer with one to two prior lines ...
Per Karlsson, MD, PhD: New Data on Breast-Conserving Surgery, With or Without Radiotherapy
Per Karlsson, MD, PhD, of Sweden’s University of Gothenburg and the Sahlgrenska Comprehensive Cancer Center, discusses results from the POLAR study, which was a meta-analysis of three clinical trials of breast-conserving surgery with or without radiotherapy. POLAR is the first genomic classifier...
Joannie M. Ivory, MD, MSPH, and Lisa A. Carey, MD, on PAM50 Subtype and 21-Gene Recurrence Scores in Younger and Black Women With Breast Cancer
Lisa A. Carey, MD, and Joannie M. Ivory, MD, MSPH, both of the University of North Carolina at Chapel Hill, discuss the higher frequency and treatment implications of nonluminal A or high-risk tumors in Black and younger women. In this study, PAM50 and 21-gene assays revealed different demographic...
Mariana Chavez-MacGregor, MD, MSc, on Adjuvant Endocrine Therapy and Everolimus in HR-Positive, HER2-Negative Breast Cancer
Mariana Chavez-MacGregor, MD, MSc, of The University of Texas MD Anderson Cancer Center, discusses phase III results from the SWOG S1207 trial which was designed to evaluate the role of adjuvant everolimus in combination with adjuvant endocrine therapy among patients with high-risk, hormone...
